Summary of findings 3. Budesonide 6 mg versus budesonide 3 mg for maintenance of remission in Crohn's disease.
Budesonide 6 mg versus budesonide 3 mg for maintenance of remission in Crohn's disease | ||||||
Patient or population: patients with quiescent Crohn's disease Settings: outpatients Intervention: budesonide 6 mg versus budesonide 3 mg | ||||||
Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
Assumed risk | Corresponding risk | |||||
Control | Budesonide 6 mg versus budesonide 3 mg | |||||
Continued remission at 3 months | 589 per 10001 | 630 per 1000 (501 to 789) | RR 1.07 (0.85 to 1.34) | 180 (3 studies) | ⊕⊕⊕⊝ Moderate2 | |
Continued remission at 6 months | 489 per 10001 | 548 per 1000 (416 to 719) | RR 1.12 (0.85 to 1.47) | 180 (3 studies) | ⊕⊕⊕⊝ Moderate3 | |
Continued remission at 12 months | 389 per 10001 | 459 per 1000 (331 to 642) | RR 1.18 (0.85 to 1.65) | 180 (3 studies) | ⊕⊕⊕⊝ Moderate4 | |
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: risk ratio | ||||||
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. |
1 Control group risk estimates come from control arm of meta‐analysis, based on included trials. 2 Sparse data (109 events). 3 Sparse data (94 events). 4 Sparse data (77 events).